{"analyses":[{"ciLowerLimit":"0.473","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.797","groupDescription":"ITT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.614","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.458","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.785","groupDescription":"ITT-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.600","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.379","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.791","groupDescription":"TC1/2/3 or IC1/2/3 ITT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0011","paramType":"Hazard Ratio (HR)","paramValue":"0.548","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.381","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.798","groupDescription":"TC1/2/3 or IC1/2/3 ITT WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0014","paramType":"Hazard Ratio (HR)","paramValue":"0.551","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"7.9","value":"6.2"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"5.8","value":"5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"ITT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"8.0","value":"6.7"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"5.8","value":"5.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"ITT-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"9.0","value":"7.2"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"6.1","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"TC1/2/3 or IC1/2/3 ITT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"9.0","value":"7.2"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"6.1","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"TC1/2/3 or IC1/2/3 ITT WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-l1 Expression WT Population","reportingStatus":"POSTED","timeFrame":"Up to approximately 35 months after first subject enrolled","title":"Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population","type":"SECONDARY","unitOfMeasure":"Months"}